Pulse Biosciences Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Paul LaViolette

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenureno data
CEO ownershipn/a
Management average tenure2.8yrs
Board average tenure7.2yrs

Recent management updates

Recent updates


CEO

Paul LaViolette (66 yo)

no data

Tenure

Mr. Paul Arthur LaViolette is President, Chief Executive Officer, Principal Executive Officer and Principal Financial Officer at Pulse Biosciences, Inc. since January 9, 2025 and was its Independent Co-Cha...


Leadership Team

NamePositionTenureCompensationOwnership
Robert Duggan
Executive Co-Chairman7.2yrsUS$257.41k77.97%
€ 901.7m
Darrin Uecker
CTO & Director2.3yrsUS$5.39m0.25%
€ 2.8m
Mitchell Levinson
Chief Strategy Officer3.4yrsUS$1.69m0.23%
€ 2.6m
Kevin Danahy
Chief Commercial Officer & Principal Executive Officerless than a yearUS$5.86m0.059%
€ 686.8k
Paul LaViolette
Presidentno datano datano data
Edison Manuel
Vice President of Operations7.8yrsno datano data
Richard Nuccitelli
Chief Science Officer10.2yrsno datano data
Kenneth B. Stratton
General Counsel & Corporate Secretary3.7yrsno datano data
Patty Perla
Vice President of Human Resources5yrsno datano data
David Danitz
Senior Vice President of Engineering3.3yrsno datano data
Gansevoort Dunnington
Chief Medical Officer1.7yrsno datano data
Niv Ad
Chief Science Officer of Cardiac Surgery1.3yrsno datano data

2.8yrs

Average Tenure

61yo

Average Age

Experienced Management: 6L8's management team is considered experienced (2.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Robert Duggan
Executive Co-Chairman7.2yrsUS$257.41k77.97%
€ 901.7m
Darrin Uecker
CTO & Director9.3yrsUS$5.39m0.25%
€ 2.8m
Paul LaViolette
Presidentless than a yearno datano data
Richard van den Broek
Independent Director4.4yrsUS$208.89k0%
€ 0
Mahkam Zanganeh
Independent Director7.9yrsUS$173.00k1.32%
€ 15.3m
Manmeet Soni
Lead Independent Director7.2yrsUS$180.07k0%
€ 0

7.2yrs

Average Tenure

58yo

Average Age

Experienced Board: 6L8's board of directors are considered experienced (7.2 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/22 18:31
End of Day Share Price 2025/01/22 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Pulse Biosciences, Inc. is covered by 3 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Swayampakula RamakanthH.C. Wainwright & Co.
Anthony VendettiMaxim Group
Christopher CooleyStephens, Inc.